Page 52 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $2.84
52wk Low $0.68 Connect Biopharma Holding CNTB $1.01
12265 El Camino Real
San Diego, CA 92130

(USD - in millions) www.connectbiopharm.com
Market Cap 54.7
Enterprise (55.2)
Basic Shares Out. 55.25 COMPANY OVERVIEW
Float 14.79
Institutional Holdings 11.56% Detailed Analysis:Channelchek.com
Short Interest 0.03
Avg. 90-Day Volume 0.03 Connect Biopharma is a global, clinical-stage biopharmaceutical
company developing innovative therapies to treat inflammatory
diseases with the goal of improving the lives of millions of those
affected around the world. The Company’s lead product candidate,
EPS Data rademikibart (formerly known as CBP-201), is an antibody designed to
target interleukin-4 receptor alpha (IL-4Rα) and has demonstrated
2022 2023 2024 activity in both atopic dermatitis and asthma. The Company’s second
CQ1 (0.53) N/A N/A product candidate, icanbelimod (formerly known as CBP-307), is a
CQ2 (0.53) N/A N/A modulator of S1P1 T cell receptors and has demonstrated activity in
ulcerative colitis.
CQ3 (0.50) N/A N/A
CQ4 (0.45) N/A N/A
CY (2.11) (1.08) (0.20) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 2.00
ROE (ttm) -17.92
Debt-to-Total Cap. (mrq) 0.29
Fiscal Year End 31-Dec

12265 El CamSan Diego CA 92130

Key Executives
CEO: Quart, Barry
CFO: N/A
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures